Blood Glucose Regulation & Diabetes Biochemistry

Blood glucose is held within a tight window (fasting 70–100 mg/dL) by an exquisitely balanced interplay of insulin against the counter-regulatory hormones glucagon, cortisol, adrenaline and growth hormone. This note builds the biochemical logic from hormone action through the molecular lesions of type 1 and type 2 diabetes, the diagnostic role of HbA1c, the metabolic crises (DKA vs HHS) and the polyol pathway behind chronic complications — the highest-yield carbohydrate-metabolism cluster for NEET PG.

Normal glucose homeostasis: the players

Glucose is the obligate fuel of brain, RBCs (no mitochondria), renal medulla and lens. The body never lets it run out — even brief hypoglycaemia is sensed faster and corrected harder than hyperglycaemia, because neuroglycopenia is lethal within minutes.

Hormone	Source	Net effect on glucose	Key actions
Insulin	β-cells, islets of Langerhans	↓ (only hypoglycaemic hormone)	↑ GLUT4 in muscle/fat, ↑ glycogenesis, ↑ lipogenesis, ↓ gluconeogenesis, ↓ lipolysis
Glucagon	α-cells	↑	↑ Glycogenolysis, ↑ gluconeogenesis, ↑ ketogenesis (liver)
Adrenaline	Adrenal medulla	↑	↑ Glycogenolysis (liver+muscle), ↑ lipolysis, ↓ insulin release
Cortisol	Adrenal cortex	↑ (slow)	↑ Gluconeogenesis, ↑ proteolysis, peripheral insulin resistance
Growth hormone	Anterior pituitary	↑	Anti-insulin, ↑ lipolysis

High-yield: Insulin is the only hormone that lowers blood glucose. All counter-regulatory hormones (glucagon, adrenaline, cortisol, GH) raise it — this redundancy explains why isolated insulin deficiency causes diabetes but no single counter-regulatory deficiency causes fatal hypoglycaemia.

Insulin biosynthesis and secretion

Preproinsulin → (signal peptide cleaved) → proinsulin → packaged in secretory granules where prohormone convertases (PC1/3, PC2) and carboxypeptidase E cleave out C-peptide, yielding mature insulin (A + B chains linked by 2 disulphide bonds). Insulin and C-peptide are secreted in equimolar amounts.

High-yield: C-peptide has a longer half-life and is not present in exogenous (pharmaceutical) insulin. Therefore C-peptide is low in type 1 DM and in factitious insulin overdose, but high in insulinoma and sulfonylurea abuse. This is the single best lab to separate endogenous from injected hyperinsulinaemia.

Glucose-stimulated insulin secretion — the stepwise flow:

1. Glucose enters β-cell via GLUT2 (high Km, non-saturating glucose sensor)
2. Glucokinase (the rate-limiting "glucose sensor," low affinity, not inhibited by G6P) phosphorylates glucose
3. Glycolysis + oxidation ↑ intracellular ATP/ADP ratio
4. ATP closes the K_ATP channel (SUR1/Kir6.2 subunits) → membrane depolarisation
5. Voltage-gated Ca²⁺ channels open → Ca²⁺ influx
6. Ca²⁺ triggers exocytosis of insulin granules

High-yield: Sulfonylureas (glibenclamide, glimepiride) close the K_ATP channel directly (bind SUR1), bypassing the need for high glucose — hence they cause hypoglycaemia. Diazoxide opens the channel (→ ↓ insulin, used in insulinoma/nesidioblastosis). Neonatal diabetes (Kir6.2 mutation) responds to sulfonylureas.

Insulin receptor signalling

Insulin receptor = receptor tyrosine kinase (α₂β₂). Insulin binds α-subunits → autophosphorylation of β-subunit tyrosines → recruits IRS-1/2 → activates PI3K → Akt (PKB) pathway → translocation of GLUT4 vesicles to membrane in muscle and adipose tissue (the insulin-responsive transporter). The Ras-MAPK arm mediates growth/mitogenic effects.

GLUT	Location	Feature
GLUT1	RBC, brain, basal	Basal uptake, high affinity
GLUT2	Liver, β-cell, kidney, gut	Low affinity, "sensor," bidirectional
GLUT3	Neurons	Highest affinity (brain priority)
GLUT4	Muscle, adipose	Insulin-dependent
GLUT5	Intestine, sperm	Fructose transporter

Type 1 vs Type 2 diabetes: biochemical basis

Type 1 DM — autoimmune T-cell-mediated destruction of β-cells → absolute insulin deficiency. Associated with HLA-DR3/DR4, DQ; autoantibodies (GAD65, IA-2, insulin, ZnT8). Prone to ketoacidosis because unopposed glucagon drives ketogenesis. Lean, young, C-peptide low/absent.

Type 2 DM — insulin resistance + relative secretory defect. Begins with peripheral resistance (post-receptor defect in PI3K/Akt, ↓ GLUT4 translocation), compensatory hyperinsulinaemia, then β-cell exhaustion. Strong genetic/lifestyle link, islet amyloid (amylin/IAPP) deposition, obesity, acanthosis nigricans. Ketosis-resistant (residual insulin suppresses lipolysis).

Feature	Type 1	Type 2
Defect	Absolute insulin deficiency	Insulin resistance ± relative deficiency
Onset / body habitus	Young, lean	Older, obese
Autoantibodies	Present (GAD65 etc.)	Absent
C-peptide	Low/absent	Normal/high (early)
Ketosis	Common (DKA)	Resistant (HHS)
HLA association	DR3/DR4, DQ	None significant
Islet pathology	Insulitis	Amyloid (amylin)
Concordance in twins	~50%	~90%

High-yield: MODY (Maturity-Onset Diabetes of the Young) is autosomal dominant, non-obese, non-ketotic, < 25 yr. MODY2 = glucokinase mutation (mild, stable hyperglycaemia); MODY3 = HNF1α (most common, sulfonylurea-sensitive). MODY is monogenic — a classic exam trap distinct from T1/T2.

Glycated haemoglobin (HbA1c)

HbA1c forms by non-enzymatic glycation — glucose attaches to the N-terminal valine of the haemoglobin β-chain via an irreversible Amadori rearrangement (a slow, ketoamine product). It reflects mean glycaemia over the preceding 8–12 weeks (RBC lifespan ~120 days).

HbA1c	Category (ADA)
< 5.7%	Normal
5.7–6.4%	Prediabetes
≥ 6.5%	Diabetes
Target	< 7% (general), individualised

High-yield: Estimated average glucose (eAG) = 28.7 × HbA1c − 46.7 (mg/dL). HbA1c 6% ≈ 126 mg/dL; each 1% rise ≈ +28–29 mg/dL.

Falsely LOW HbA1c: haemolytic anaemia, recent blood loss/transfusion, pregnancy, erythropoietin therapy (young RBCs). Falsely HIGH HbA1c: iron-deficiency anaemia, B12/folate deficiency, splenectomy, uraemia (carbamylated Hb), alcoholism. HbF, HbS, HbC variants interfere depending on assay.

High-yield: Other glycation markers — fructosamine (glycated albumin) reflects ~2–3 weeks; 1,5-anhydroglucitol reflects short-term/postprandial control. Use fructosamine when HbA1c is unreliable (haemoglobinopathy, pregnancy).

Diagnosis of diabetes (ADA criteria)

Any one of (confirmed on repeat unless unequivocal symptoms):

1. Fasting plasma glucose ≥ 126 mg/dL (8 h fast)
2. 2-h OGTT ≥ 200 mg/dL (75 g glucose load)
3. HbA1c ≥ 6.5%
4. Random glucose ≥ 200 mg/dL + classic symptoms (polyuria, polydipsia, weight loss)

Investigation of choice for diagnosis in ambiguous/borderline cases = OGTT; for monitoring = HbA1c; gestational DM screened by OGTT.

Acute crises: DKA vs HHS

Diabetic ketoacidosis (DKA): Severe insulin deficiency + ↑ glucagon → unrestrained lipolysis → free fatty acids to liver → β-oxidation → acetyl-CoA floods → ketogenesis. The rate-limiting enzyme is HMG-CoA synthase (mitochondrial). Ketone bodies = acetoacetate, β-hydroxybutyrate (predominant; a reduced product favoured by high NADH), and acetone (breath odour). High-anion-gap metabolic acidosis.

Hyperosmolar hyperglycaemic state (HHS): Enough residual insulin to suppress lipolysis/ketogenesis but not hyperglycaemia → extreme hyperglycaemia, profound dehydration, hyperosmolarity, minimal ketosis, altered sensorium/coma. Typically elderly type 2.

Feature	DKA	HHS
Typical patient	Type 1 (young)	Type 2 (elderly)
Glucose	250–600 mg/dL	> 600 (often > 1000) mg/dL
Ketones	Strongly positive	Absent/trace
Arterial pH	< 7.3 (acidotic)	> 7.3 (normal)
Bicarbonate	< 18 mEq/L	> 18 mEq/L
Serum osmolality	Variable	> 320 mOsm/kg
Anion gap	High	Normal/mild
Mortality	Lower	Higher

High-yield: In DKA the nitroprusside test detects acetoacetate but NOT β-hydroxybutyrate — so as the patient improves and β-OHB converts back to acetoacetate, ketones may appear to rise on bedside testing despite clinical improvement. Measure β-hydroxybutyrate directly.

Management flow of DKA: Fluids (normal saline) first → Insulin (regular IV infusion) → Potassium replacement (insulin drives K⁺ intracellularly) → correct precipitant. Drug of choice = regular (short-acting) insulin IV infusion. Watch for hypokalaemia and cerebral oedema (especially in children).

Chronic complications: the polyol (sorbitol) pathway

In insulin-independent tissues (lens, retina, nerve, kidney, RBC), excess glucose enters the polyol pathway:

Glucose → (aldose reductase, uses NADPH) → Sorbitol → (sorbitol dehydrogenase, makes NADH) → Fructose

Sorbitol is poorly membrane-permeable and accumulates → osmotic damage + ↓ NADPH (less glutathione regeneration → oxidative stress). This underlies diabetic cataract, retinopathy, neuropathy, nephropathy.

High-yield: Aldose reductase is the key/rate-limiting enzyme of the polyol pathway and the target of aldose reductase inhibitors (epalrestat). NADPH consumption links it to oxidative stress. Same mechanism in galactosaemia (galactose → galactitol → infantile cataract).

Other mechanisms: non-enzymatic glycation → AGEs (advanced glycation end-products) crosslink collagen, thicken basement membranes; PKC activation; hexosamine pathway. AGEs drive microvascular disease.

Complications: microvascular (retinopathy, nephropathy — Kimmelstiel-Wilson nodular glomerulosclerosis, neuropathy) and macrovascular (CAD, stroke, PVD). Earliest renal marker = microalbuminuria.

Management & drugs of choice (biochemical targets)

Drug class	Molecular target	Note
Metformin	↓ Hepatic gluconeogenesis (AMPK activation, ↓ mitochondrial complex I)	First-line in T2DM; lactic acidosis risk
Sulfonylureas	Close β-cell K_ATP channel	Hypoglycaemia, weight gain
SGLT2 inhibitors	Block renal glucose reabsorption (PCT)	Cardio-renal benefit, euglycaemic DKA risk
GLP-1 agonists	Incretin, ↑ glucose-dependent insulin	Weight loss
DPP-4 inhibitors	↑ endogenous incretins	Weight neutral
Thiazolidinediones	PPAR-γ agonist, ↑ insulin sensitivity	Fluid retention
α-glucosidase inhibitors	↓ intestinal carb digestion (acarbose)	Postprandial

High-yield: Metformin is the first-line drug for type 2 DM; it does not cause hypoglycaemia or weight gain. Insulin is the drug of choice for type 1 DM, DKA, pregnancy, and any severe hyperglycaemia.

Key differentials

• Hypoglycaemia work-up: Insulinoma (↑ insulin, ↑ C-peptide, ↑ proinsulin), sulfonylurea abuse (↑ insulin, ↑ C-peptide, drug screen +), exogenous insulin (↑ insulin, ↓ C-peptide). Whipple's triad confirms hypoglycaemia.
• Glycosuria without diabetes: renal glycosuria (SGLT2 mutation, normal blood glucose), pregnancy.
• DKA mimics: alcoholic ketoacidosis, starvation ketosis, lactic acidosis, salicylate poisoning, uraemia (other high-anion-gap acidoses — MUDPILES).
• Secondary diabetes: Cushing (cortisol), acromegaly (GH), phaeochromocytoma (catecholamines), pancreatitis, haemochromatosis ("bronze diabetes"), drugs (steroids, thiazides).

Recently asked / exam angle

• C-peptide interpretation to distinguish insulinoma vs exogenous insulin vs sulfonylurea — perennial favourite.
• Glucokinase as the β-cell glucose sensor; MODY2 link; not inhibited by its product G6P (vs hexokinase, which is).
• HbA1c falsely altered by anaemias — iron deficiency raises it, haemolysis lowers it.
• eAG formula numerical conversions (HbA1c 7% → ~154 mg/dL).
• Aldose reductase / sorbitol as cause of diabetic cataract and neuropathy; NADPH depletion.
• K_ATP channel pharmacology (sulfonylurea closes vs diazoxide opens) and neonatal diabetes.
• β-hydroxybutyrate vs nitroprusside test pitfall in DKA monitoring.
• GLUT4 as the only insulin-dependent transporter; GLUT2 as low-affinity liver/β-cell sensor.
• DKA vs HHS osmolality and pH cut-offs.

Rapid revision

1. Insulin is the only hypoglycaemic hormone; all others raise glucose.
2. Insulin & C-peptide are secreted equimolar — C-peptide low in T1DM and exogenous insulin overdose, high in insulinoma/sulfonylurea.
3. β-cell glucose sensor = GLUT2 + glucokinase; ATP closes K_ATP channel → depolarisation → Ca²⁺ → insulin exocytosis.
4. Sulfonylureas close, diazoxide opens the K_ATP channel.
5. GLUT4 (muscle/adipose) is the insulin-dependent transporter; GLUT5 carries fructose.
6. HbA1c ≥ 6.5% diagnoses diabetes; reflects 8–12 weeks; eAG = 28.7 × A1c − 46.7.
7. Iron deficiency raises HbA1c; haemolysis/blood loss/pregnancy lower it; use fructosamine if unreliable.
8. Metformin = first-line T2DM (AMPK, ↓ gluconeogenesis, no hypoglycaemia); insulin = DOC for T1DM/DKA/pregnancy.
9. DKA: pH < 7.3, HCO₃ < 18, ketones +, β-OHB predominant; HHS: glucose > 600, osmolality > 320, no acidosis.
10. DKA management order: fluids → insulin → potassium; watch hypokalaemia and cerebral oedema.
11. Aldose reductase converts glucose → sorbitol (uses NADPH) → cataract, neuropathy, retinopathy.
12. MODY is monogenic AD; MODY2 = glucokinase, MODY3 = HNF1α (sulfonylurea-sensitive); HLA DR3/DR4 = type 1.